Stock 2 Trial

The chart shows the growth of an initial investment of $10,000 in Stock 2 Trial, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.

Based on dividend-adjusted daily data since Jan 12, 2024, Stock 2 Trial's average daily return is +0.12%, while the average monthly return is +3.38%. At this rate, an investment would double in approximately 1.7 years.

Historically, 71% of months were positive and 29% were negative. The best month was Feb 2024 with a return of +18.1%, while the worst month was Mar 2025 at -7.1%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 2 months.

On a daily basis, Stock 2 Trial closed higher 38% of trading days. The best single day was Apr 9, 2025 with a return of +12.2%, while the worst single day was Jan 27, 2025 at -6.1%.

Stock 2 Trial has an annualized alpha of 21.50%, beta of 1.37, and R² of 0.70 versus S&P 500 Index. Calculated based on daily prices since January 12, 2024.

• This portfolio captured 220.37% of S&P 500 Index gains but only 86.60% of its losses — a favorable profile for investors.
• This portfolio generated an annualized alpha of 21.50% versus S&P 500 Index — delivering returns beyond what market exposure alone would predict.

Stock 2 Trial has an expense ratio of 0.08%, which is considered low. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

Stock 2 Trial ranks 35 for risk / return — below 35% of portfolios on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Stock 2 Trial Sharpe ratios as of Apr 11, 2026 (values are recalculated daily):

• 1-Year: 2.65
• All Time: 1.86

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

Compared to the broad market, where average Sharpe ratios range from 2.14 to 3.05, this portfolio's current Sharpe ratio falls between the 25th and 75th percentiles. This indicates that its risk-adjusted performance is in line with the majority of portfolios, suggesting a balanced approach to risk and return—likely suitable for a wide range of investors.

The chart below shows the rolling Sharpe ratio of Stock 2 Trial compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

Stock 2 Trial provided a 0.24% dividend yield over the last twelve months.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Stock 2 Trial. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Stock 2 Trial was 22.18%, occurring on Apr 8, 2025. Recovery took 56 trading sessions.

The current Stock 2 Trial drawdown is 5.54%.

The chart below shows the rolling one-month volatility.